New clinical evidence suggests COVID-19 antivirals like Paxlovid show limited benefit for vaccinated individuals, triggering a sharp decline in sales for manufacturers like Pfizer. As regulatory bodies review subsidy programs, pharmaceutical companies are facing pressure to pivot their business models away from pandemic-era products.
New research has cast doubt on the effectiveness of COVID-19 antivirals such as Paxlovid and Lagevrio for individuals who are already vaccinated or have prior infection immunity. Recent clinical trials, including the PANORAMIC and CanTreatCOVID studies, have indicated that these treatments offer a negligible reduction in hospitalisations or deaths among these protected groups. This shift in scientific understanding is challenging the widespread use of these drugs, which were once considered essential tools in the fight against the pandemic.
The findings have significant financial implications for the pharmaceutical sector. Pfizer, the manufacturer of Paxlovid, has reported a sharp decline in COVID-19 product revenues throughout 2026, with some estimates citing a drop of 70% to 95% in sales. This slump has forced the company to revise its revenue outlooks, prompting investors to scrutinise the sustainability of pandemic-related income streams.
Regulatory scrutiny is also intensifying. In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) is scheduled to review the cost-effectiveness and public subsidy status of COVID-19 antivirals later in 2026. Similar assessments are occurring in other regions, as governments evaluate whether these drugs still provide enough value to warrant continued government funding under schemes like the Pharmaceutical Benefits Scheme (PBS).
For investors, the situation highlights the risks associated with pandemic-era therapeutics. As the market for COVID-19 treatments becomes more volatile and demand wanes, companies are under pressure to demonstrate their ability to generate long-term growth. Many are now focusing on shifting their portfolios toward other high-growth areas, such as oncology and treatments for obesity, to offset the losses from their COVID-19 portfolios.
Going forward, the primary monitorables for stakeholders will be the outcomes of these upcoming regulatory reviews and the ability of pharmaceutical firms to successfully execute their R&D pivots. Shareholders will also likely watch for upcoming quarterly earnings to assess how quickly these companies can replace the declining pandemic-related revenue with new, sustainable product lines.